CClinicalTrials.gg
CompletedNCT03057041Updated Jun 13, 2018

Intranasal Fentanyl for Pain Control During First-Trimester Uterine Aspiration

An interventional study of Fentanyl and placebo in Pain Uterus, sponsored by University of Hawaii. Completed at 2 sites in United States. Open to female participants aged 14 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2018-06-13.

Sponsored by University of Hawaii · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
107
Allocation
Randomized
Ages
14 Years and older
Sex
Female
01

Study summary

Intranasal fentanyl has been found to be safe and effective in the reduction of pain among pediatric and adult populations. The investigators hypothesize that patients who receive 100 mcg of intranasal fentanyl for pain control before first-trimester uterine aspiration will report lower pain scores than those who receive placebo. The investigators will test this hypothesis using a randomized, double-blind, placebo-controlled trial comparing pain reported during uterine aspiration between patients who receive either intranasal fentanyl or intranasal saline prior to the procedure.

02

Conditions studied

  • Pain Uterus
03

In context

Lead sponsor

University of Hawaii is the lead sponsor of 95 studies on the registry; 20 are open to participants now.

Of its 7 completed or terminated interventional studies of FDA-regulated products, 3 (43%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
14 Years and older
Sexes eligible
Female
Accepts healthy volunteers
Yes

Inclusion criteria

  • Seeking office based uterine aspiration
  • Gestational age at 14 weeks or less
  • Age 14 years or older with parental consent to participate in this research study if 14-17 years old
  • Able to read, speak, and understand English
  • Ability to understand materials and consent forms

Exclusion criteria

Exclusion Criteria:

  • Seeking medical abortion, operating room based surgical abortion, or operating room based miscarriage management
  • Gestational age greater than 14 weeks
  • Age less than 14 years old
  • Inability to read, speak, and understand English
  • Current incarceration
  • Weight less than 40kg
  • Self-reported or documentation of significant cardiopulmonary disease
  • Self-reported or documentation of alcohol or substance dependence or abuse
  • Contraindications, relative contraindication to fentanyl use
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
107 participants (actual)

Study arms

  • Experimental
    Fentanyl

    Drug: Fentanyl

  • Placebo comparator
    Placebo

    Drug: placebo

Interventions

  • DrugFentanyl

    100 mcg of intranasal fentanyl, 50 mcg/ mL in each nostril via mucosal atomizer 15 minutes prior to procedure start

  • Drugplacebo

    1 mL of sterile saline in each nostril via mucosal atomizer 15 minutes prior to procedure start

06

What researchers measure

Primary outcomes

  1. Pain during uterine aspiration

    Self reported on 100 mm VAS

    Time frame: During uterine aspiration or immediately after uterine aspiration

Secondary outcomes

  1. Patient satisfaction with procedural pain control

    Self reported on 100 mm VAS

    Time frame: approximately 15 minutes after procedure ends

  2. Post-procedural pain

    Self reported on 100 mm VAS

    Time frame: approximately 15 minutes after procedure end

07

Study locations

2 sites
  • Women's Options Center
    Honolulu, Hawaii 96826, United States
  • Planned Parenthood Columbia Willamette
    Portland, Oregon 97212, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jun 13, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03057041
Lead sponsor
University of Hawaii
Collaborators
Society of Family Planning
Responsible party
Sponsor
First posted
Feb 17, 2017
Start date
Mar 23, 2017
Primary completion
May 30, 2018
Completion
May 30, 2018
Last update
Jun 13, 2018

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion